Bernstein raised the firm’s price target on Dyne Therapeutics (DYN) to $21 from $12 and keeps a Market Perform rating on the shares. The firm sees Dyne’s risk-reward as favorable even following the recent move. Next catalyst is for DYN-251 in Duchenne Muscular Dystrophy with data for the registrational expansion cohort.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target lowered to $17 from $18 at JPMorgan
- Dyne Therapeutics price target lowered to $11 from $13 at Oppenheimer
- Dyne Therapeutics price target lowered to $38 from $41 at Evercore ISI
- Dyne Therapeutics price target raised to $46 from $38 at H.C. Wainwright
- Positive Outlook for Dyne Therapeutics: Strong Financial Performance and Promising Clinical Developments Support Buy Rating